Zobrazeno 1 - 10
of 326
pro vyhledávání: '"M. K. B. Parmar"'
Autor:
Per Kragh Andersen
Publikováno v:
Statistics in Medicine. 16:714-715
Autor:
C C, Parker, N W, Clarke, C, Catton, H, Kynaston, A, Cook, W, Cross, C, Davidson, C, Goldstein, J, Logue, C, Maniatis, P M, Petersen, P, Neville, H, Payne, R, Persad, C, Pugh, A, Stirling, F, Saad, W R, Parulekar, M K B, Parmar, M R, Sydes
Publikováno v:
Clinical Oncology. 34:593-597
Autor:
Gordon C Jayson, A C Embleton-Thirsk, Stan B. Kaye, Timothy J. Perren, M K B Parmar, E Deane, J. A. Ledermann, Antonio González-Martín, H. Hirte, Michelle Margaret Vaughan, Laura Farrelly, Richard Kaplan, Amit M. Oza, Ann Marie Swart, G. J. S. Rustin, B Popoola, Michael Friedlander
Publikováno v:
ESMO Open
Background Cediranib, an oral anti-angiogenic VEGFR 1-3 inhibitor, was studied at a daily dose of 20 mg in combination with platinum-based chemotherapy and as maintenance in a randomised trial in patients with first relapse of ‘platinum-sensitive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d15558f2ba412cbdd748ee1254af17b
https://ueaeprints.uea.ac.uk/id/eprint/79569/
https://ueaeprints.uea.ac.uk/id/eprint/79569/
Autor:
ANDERSEN, PER KRAGH
Publikováno v:
Statistics in Medicine; March 1997, Vol. 16 Issue: 6 p714-715, 2p
Autor:
C L, Vale, D J, Fisher, I R, White, J R, Carpenter, S, Burdett, N W, Clarke, K, Fizazi, G, Gravis, N D, James, M D, Mason, M K B, Parmar, L H, Rydzewska, C J, Sweeney, M R, Spears, M R, Sydes, J F, Tierney
Publikováno v:
Annals of Oncology
Background Our prior Systemic Treatment Options for Cancer of the Prostate systematic reviews showed improved survival for men with metastatic hormone-naive prostate cancer when abiraterone acetate plus prednisolone/prednisone (AAP) or docetaxel (Doc
Autor:
M K B Parmar, M. Toi, Friedrich Overkamp, Peter Hall, David Cameron, Thomas M. Suter, Günther G. Steger, Christian Jackisch, Richard Bell, Louise Provencher, Julia Brown, Laurence Vanlemmens, Xavier Pivot, Leilani Morales, John R. Mackey, N. Xu, Norikazu Masuda, Andreas Schneeweiss, Roberto Hegg, Rebecca Dent, Andreas Kirsch
Publikováno v:
Bell, R, Brown, J, Parmar, M, Toi, M, Suter, T, Steger, G G, Pivot, X, Mackey, J, Jackisch, C, Dent, R, Hall, P, Xu, N, Morales, L, Provencher, L, Hegg, R, Vanlemmens, L, Kirsch, A, Schneeweiss, A, Masuda, N, Overkamp, F & Cameron, D 2016, ' Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer ', Annals of Oncology . https://doi.org/10.1093/annonc/mdw665
The purpose of this analysis was to assess the long-term impact of adding bevacizumab to adjuvant chemotherapy for early triple-negative breast cancer (TNBC).Patients eligible for the open-label randomized phase III BEATRICE trial had centrally confi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ffe6de32384a25fcbbfe30f8e90336c
Autor:
A. du Bois, M K B Parmar, Jonathan A. Ledermann, Antonio González-Martín, Nicoletta Colombo, Fharat A. Raja, Ignace Vergote, Nicholas Counsell, David S. Alberts, Valter Torri, Jacobus Pfisterer, Marie Plante
Publikováno v:
Annals of Oncology. 24:3028-3034
The majority of women with ovarian cancer develop recurrent disease. For patients with a platinum-free interval of >6 months, platinum-based chemotherapy is a treatment of choice. The benefit of platinum-based combination chemotherapy in randomized t
Autor:
Ruth E Langley, M K B Parmar, Matthew Nankivell, C. Pugh, Richard Stephens, Barbara Moore, Neal Navani, P. Wilson, R Barton, Corinne Faivre-Finn, P. Mulvenna
Publikováno v:
Clinical Oncology. 25:e23-e30
Over 30% of patients with non-small cell lung cancer (NSCLC) develop brain metastases. If inoperable, optimal supportive care (OSC), including steroids, and whole brain radiotherapy (WBRT) are generally considered to be standard care, although there
Publikováno v:
Annals of Oncology. 22:vii57-vii61
This supplement has explored the evidence for benefits from the participation of healthcare institutions and their patients in clinical research. The questions have been clarified. There is some encouragement that research active healthcare instituti
Autor:
M K B Parmar, Wendi Qian, Fharat A. Raja, H Hirte, Clare L. Griffin, Ann Marie Swart, Jonathan A. Ledermann
Publikováno v:
British Journal of Cancer
Background: Cediranib is a potent oral vascular endothelial growth factor (VEGF) signalling inhibitor with activity against all three VEGF receptors. The International Collaboration for Ovarian Neoplasia 6 (ICON6) trial was initiated based on evidenc